National Cultures and International Competition: The Experience of Schering AG, 18511950: The Experience of Schering AG, 1851-1950 (Cambridge Studies in the Emergence of Global Enterprise)
The Independent (Free subscription) | 19/11/2009
The Asia-Pacific market for contraceptives should post strong growth in the next decade as women shed their fears and new products are introduced, drugs giant Bayer Schering Pharma said Wednesday.
Market Wire (Free subscription) | 18/11/2009
NEW YORK, NY (MARKET WIRE) Bayer Schering Pharma and ExL Pharma today announced that the 2nd Annual Digital Pharma Europe and 2nd Annual European Public Relations and Communications Summit will be hosted at the Bayer Schering Pharma World Headquarters in Berlin, Germany on March 29-30, 2010.
France24 (Free subscription) | 18/11/2009
The Asia-Pacific market for contraceptives should post strong growth in the next decade as women shed their fears and new products are introduced, drugs giant Bayer Schering Pharma said Wednesday. China, India and Vietnam are among the key growth areas for the region, where the use of reliable birth control methods remains low, said Phil Smits, head of the Women's Healthcare Global Business Unit at...
Business Wire (Free subscription) | 11/11/2009
MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE Amex:OPK) today announced that it has completed the acquisition of rolapitant and a related compound from Schering Corporation, a subsidiary of Merck & Co., Inc. ("Schering"). Rolapitant, a neurokinin-1 (NK-1) receptor antagonist, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy...
2009 2010International Scholarships (Free subscription) | 10/11/2009
Post-doc or PhD position Netherlands Metabolomics Center Prednisolone induced metabolite profiles in human and mouse: Crossspecies translation and cross-omics integration. A 3-years post-doc position or 4 years PhD student position is available within the Netherlands Metabolomics Center, in a joint project between Schering- Plough, Leiden/Amsterdam Center for Drug Research (LACDR), TNO Zeist and Radboud...
aids-write.org (Free subscription) | 09/11/2009
Larger Merck says merger will actually increase R&D efficiency pharmatimes.com 05 November 2009 The new Merck & Co has opened its doors for business, and the company has been laying out its plans for future growth now that Schering-Plough has been added to the group. Chief executive Richard Clark says that “our integration teams prepared us [...]
The IN VIVO Blog (Free subscription) | 06/11/2009
In case you failed to run a Google search this week, you may not have realized that on Tuesday Nov. 10, Sesame Street turns 40 . You gotta admit, the show doesn't look a day over five--and that's without Botox. If you've forgotten how to get to Sesame Street , we have a few reminders--and ear worms -- appropriately tailored for the biopharma industry--hey, it's our version of personalized medicine...
PharmaGossip (Free subscription) | 05/11/2009
To Schering we bid our fondest adieu; Founder Ernst might weep at the shame. Your German sibling has shuffled off, too, But Bayer, at least, saved his name. Source
Seattle Times (Free subscription) | 04/11/2009
A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough.
Seattle Post-Intelligencer (Free subscription) | 04/11/2009
NEW YORK -- A day after drugmaker Merck & Co. completed its $41.1 billion purchase of rival Schering-Plough Corp., Fitch Ratings Service on Wednesday cut its ratings on Merck and upgraded Schering-Plough.
Stocks to Watch Today (Free subscription) | 04/11/2009
Merck, as expected, closes on Schering acquisition
Philadelphia Inquirer (Free subscription) | 04/11/2009
Merck & Co. Inc. completed its planned $41 billion acquisition of Schering-Plough Corp. yesterday after the stock markets closed. The deal creates the world's second-largest drugmaker, behind Pfizer Inc. Patent expirations on top-selling drugs such as Merck's asthma drug Singulair helped drive the combination.
Star Tribune (Free subscription) | 02/11/2009
After 28 weeks of treatment, Schering-Plough said 25 percent of the null responders had a "sustained virologic response," meaning their virus levels were too low to measure. After 48 weeks of treatment, 55 percent of patients had a sustained virologic response.
ABC News (Free subscription) | 02/11/2009
Schering posts boceprevir trial data, including results for patients not helped by other drugs
43(B)log (Free subscription) | 31/10/2009
Schering-Plough Healthcare Products, Inc. v. Schwarz Pharma, Inc., -- F.3d --, 2009 WL 3460808 (7th Cir.) As entertaining as a Posner opinion always is, I fear this one has more than enough casual language in it to do mischief to the law; it will likely be much cited, whether for heat or for light. Discussion of opinion below , dismissing Schering’s false advertising claims. Schering sells an...
Videos